59Z Stock Overview
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 59Z from our risk checks.
MediPal Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥15.60 |
| 52 Week High | JP¥16.90 |
| 52 Week Low | JP¥12.90 |
| Beta | 0.11 |
| 11 Month Change | -2.50% |
| 3 Month Change | 12.23% |
| 1 Year Change | -0.64% |
| 33 Year Change | -2.59% |
| 5 Year Change | n/a |
| Change since IPO | -6.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 59Z | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -0.6% | 0.7% | -1.0% |
| 1Y | -0.6% | 10.9% | 12.8% |
Return vs Industry: 59Z underperformed the German Healthcare industry which returned 10% over the past year.
Return vs Market: 59Z underperformed the German Market which returned 13.8% over the past year.
Price Volatility
| 59Z volatility | |
|---|---|
| 59Z Average Weekly Movement | 4.7% |
| Healthcare Industry Average Movement | 3.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 59Z has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 59Z's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1898 | 13,075 | Shuichi Watanabe | www.medipal.co.jp |
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprises medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; animal health products for companion animals; food processing raw materials for agriculture, fisheries, and livestock; and livestock feed additives, seasonings, veterinary medical equipment, packaging materials, industrial chemicals, and other products.
MediPal Holdings Corporation Fundamentals Summary
| 59Z fundamental statistics | |
|---|---|
| Market cap | €3.29b |
| Earnings (TTM) | €242.60m |
| Revenue (TTM) | €22.11b |
13.6x
P/E Ratio0.1x
P/S RatioIs 59Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 59Z income statement (TTM) | |
|---|---|
| Revenue | JP¥3.58t |
| Cost of Revenue | JP¥3.33t |
| Gross Profit | JP¥249.92b |
| Other Expenses | JP¥210.62b |
| Earnings | JP¥39.29b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 01, 2024
| Earnings per share (EPS) | 188.96 |
| Gross Margin | 6.98% |
| Net Profit Margin | 1.10% |
| Debt/Equity Ratio | 0% |
How did 59Z perform over the long term?
See historical performance and comparison